NanoViricides, Inc. Nears Finalization of Clinical Trial Protocol for MPox Treatment

NanoViricides, Inc. (NYSE American: NNVC) is on the brink of completing its adaptive clinical trial protocol for MPox Clade Ia and Ib, targeting around 80 patients in the Democratic Republic of Congo. This Phase II trial is structured in two parts to assess the safety, dosing, and effectiveness of NV-387 oral gummies. These gummies are specifically designed to ease administration for patients experiencing painful oral lesions, a common symptom of MPox. NV-387 could emerge as the first drug to show clinical efficacy against an orthopoxvirus in humans, providing a much-needed alternative where current treatments such as Tecovirimat and Brincidofovir have not met expectations due to limited efficacy or undesirable side effects.

The potential impact of NV-387 is not limited to MPox alone. NanoViricides has outlined plans to pursue regulatory approvals across Africa, the United States, and other global markets, including for smallpox. This initiative is especially pertinent as Clade 1b MPox remains a significant epidemic threat in Africa, with the potential to spread to Western countries. The development and eventual approval of NV-387 could mark a pivotal advancement in combating orthopoxviruses worldwide, fulfilling an urgent medical need and bolstering global pandemic readiness. For more information on the trial, visit https://www.nanoviricides.com.